IP Library Granted Patent US 11,357,753
Granted Patent B2
US 11,357,753 · App. 16/485,008 · Granted Jun 14, 2022

Rescue treatment of post operative nausea and vomiting

Inventors: Julian Clive Gilbert (Cambridge, GB); Robert William Gristwood (Cambridge, GB); Gabriel Fox (Cambridge, GB)
Assignee: Acacia Pharma Ltd
A61K31/40A61K9/0019A61K31/4178A61K31/438A61K31/439A61K31/496A61K31/5377A61K31/573A61P1/08
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,357,753
App. No.
16/485,008
Granted
Jun 14, 2022
Kind
B2
Abstract

Amisulpride is useful in the treatment of postoperative nausea and/or vomiting in a patient, wherein the patient has already been administered a prophylaxis drug for postoperative nausea and/or vomiting, and wherein the dose of amisulpride is 7.5 to 15 mg.

Claims (8)

1. A method for treating postoperative nausea and/or vomiting (PONV) in a patient, comprising administering amisulpride to the patient at a dose of 10 mg, wherein the patient has been administered a prophylaxis drug for PONV, undergone a surgical procedure, and experienced PONV prior to the administration of amisulpride, and wherein the prophylaxis drug is not amisulpride.

2. The method of claim 1 , wherein the prophylaxis drug is not a dopamine-2 (D 2 ) antagonist.

3. The method of claim 1 , wherein the prophylaxis drug is an anti-emetic selected from a 5HT 3 -antagonist, a corticosteroid, an anti-histamine (H1), an anti-cholinergic, a H 2 -antagonist and a NK 1 -antagonist.

4. The method of claim 1 , wherein the amisulpride is administered in combination with another anti-emetic, either sequentially or simultaneously.

5. The method of claim 4 , wherein the another anti-emetic is a 5HT 3 antagonist, an NK 1 antagonist or a steroid.

6. The method of claim 5 , wherein the another anti-emetic is dexamethasone, ondansetron, granisetron, palonosetron, aprepitant, netupitant or rolapitant.

7. The method of claim 1 , wherein the amisulpride is substantially in the form of a racemate.

8. The method of claim 1 , wherein the amisulpride is administered via the intravenous route.

Assignments (5)
SECURITY INTEREST Recorded Apr 27, 2026
From: LXO IRELAND DESIGNATED ACTIVITY COMPANY
To: KROLL TRUSTEE SERVICES LIMITED, AS SECURITY AGENT
Reel/Frame 074483/0163 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 4, 2026
From: ACACIA PHARMA LIMITED; ACACIA PHARMA, INC.; EAGLE PHARMACEUTICALS, INC.
To: LXO IRELAND DESIGNATED ACTIVITY COMPANY; LXO US, INC.
Reel/Frame 073967/0303 →
RELEASE OF SECURITY INTEREST Recorded Apr 1, 2025
From: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
To: ACACIA PHARMA LIMITED
Reel/Frame 070698/0351 →
SECURITY INTEREST Recorded Apr 28, 2023
From: ACACIA PHARMA LIMITED
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 063476/0631 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 10, 2019
From: GILBERT, JULIAN CLIVE; GRISTWOOD, ROBERT WILLIAM; FOX, GABRIEL
To: ACACIA PHARMA LTD
Reel/Frame 051229/0769 →
Priority Claims (1)
GB 1702250 · Feb 10, 2017 · national
Continuity (1)
Related Publication 20200038369A1 · Feb 6, 2020
Cited By (1)
US 12,329,740